KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…
Matched conditions: KRAS G12C
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated May 17, 2026 02:56 UTC
-
New combo attack on lung cancer brain tumors shows promise in early trial
Disease control Recruiting nowThis study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive both treatments. The m…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Ryan Gentzler, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with abnormal blood vessels (vascular malformations). One drug, alpelisib, is for slow-flow types; the other, mirdametinib, is for fast-flow types. About 50 participants aged 2 and older will take the drug for 48 weeks to see if thei…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New targeted drug enters human testing for hard-to-treat lung cancer
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 04, 2026 16:23 UTC